A randomized trial finds weekly extended-release buprenorphine yields neonatal outcomes comparable to sublingual treatment.

Nassau County drug rehab now offers monthly Sublocade and Vivitrol injections for opioid and alcohol addiction on Long ...

March 22, 2026 – National Institutes of Health (NIH) released the following: ...

Please provide your email address to receive an email when new articles are posted on . Brixadi is the first long-acting buprenorphine injectable that is available in weekly and monthly doses.

Weekly injectable buprenorphine is more effective than daily doses for treating opioid use disorder in pregnancy, with higher ...

LUND, Sweden, June 25, 2024 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 ...

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...

In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly ...

Please provide your email address to receive an email when new articles are posted on . New data show that rapid initiation with once-monthly Sublocade significantly improved treatment retention vs.

In a randomized trial, both 100-mg and 300-mg monthly maintenance doses of extended-release buprenorphine improved opioid abstinence in patients with high-risk opioid use, with no new safety signals.

Virtual opioid use disorder treatment company Bicycle Health is partnering with supermarket chain Albertsons to allow the telehealth company's providers to prescribe buprenorphine monthly injections ...

OAKLAND — Dr. Andrew Herring has a clear goal walking into every appointment with patients seeking medication to treat an opioid use disorder: persuade them to get an injection of extended-release ...